[1] Schwartz RS. Pathophysiology of restenosis: Interaction of thrombosis, hyperplasia, and/or remodeling[J]. Am J Cardiol. 1998; 81: 14E-17E.
[2] Casscells W, Engler D, Willerson JT. Mechanisms of restenosis[J]. Tex Heart Inst J, 1994, 21: 68-77.
[3] Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation. 1997; 96: 2280-86.
[4] Hou J, Jia H, Liu H, et al. Neointimal tissue characteristics following sirolimus-eluting stent implantation: OCT quantitative tissue property analysis[J]. Int J Cardiovasc Imaging, 2012, 28: 1879-86.
[5] Nagoshi R, Shinke T, Otake H, et al. Qualitative and quantitative assessment of stent restenosis by optical coherence tomography:comparison between drug-eluting and bare-metal stents[J]. Circ J, 2013, 77: 652-60.
[5] Lee AM, Ohtani K, Macaulay C, et al.In vivo lung microvasculature visualized in three dimensions using fiberoptic color Doppler optical coherence tomography Anthony M. D. Lee,a Keishi Ohtani,a Calum MacAulay,a[J].Bio Opt,2013,18(5):050501-1-050501-3.
[7] Folgar F A, Yuan E L, Farsiu S, et al.Lateral and axial measurement differences between spectral-domain optical coherence tomography systems[J].Bio Opt,2014,19(1):016014-1-016014-6.
[8] Otakea H, Shitea J, Ikenob F, et al. Evaluation of the peri-strut low intensity area following sirolimus- and paclitaxel-eluting stents implantation: insights from an optical coherence tomography study in humans[J]. Int J Cardiol, 2012, 157: 38-42.
[9] Nagai H, Ishibashi-Ueda H, Fujii K. Histology of highly echolucent regions in optical coherence tomography images from two patients with sirolimus-eluting stent restenosis[J]. Catheter Cardiovasc Interv, 2010, 75: 961-3.
[10] Bashore TM, Balter S, Barac A, et al. 2012 American College of CardiologyFoundation/Society for Cardiovascular Angiography and Interventions expert consensus document on cardiac catheterization laboratory standards update: a report of the American College of Cardiology Foundation Task Force on Expert Consensus documents developed in collaboration with the Society of Thoracic Surgeons and Society for Vascular Medicine[J]. J Am Coll Cardiol, 2012, 59(24): 2221-2305.
[11] Park KW, Lee JM, Kang SH, et al. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting Resolute stents in real-world practice: patient-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries[J]. J Am Coll Cardiol, 2013, 61(5):536-544.
[12] von Birgelen C, Basalus MW, Tandjung K, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial[J]. J Am Coll Cardiol, 2012, 59(15):1350-1361.
[13] Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents[J]. N Engl J Med, 2010, 363(2): 136-146.
[14] Gutiérrez-Chico JL, van Geuns RJ, Regar E, et al. Tissue coverage of a hydrophilic polymer-coated zotarolimus-eluting stent vs. a fluoropolymer-coated everolimus-eluting stent at 13-month follow-up: an optical coherence tomography substudy from the RESOLUTE All Comers trial[J]. Eur Heart J, 2011, 32(19): 2454-2463. |
